nach oben

Erschienen in:

01.03.2007 | Original Article

How important is the opinion of significant others to cancer patients’ adjuvant chemotherapy decision-making?

verfasst von: A. M. Stiggelbout, S. J. T. Jansen, W. Otten, M. C. M. Baas-Thijssen, H. van Slooten, C. J. H. van de Velde

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Goals

Decisions regarding adjuvant chemotherapy are difficult, since value tradeoffs are involved. Little is known about the importance of the significant others in patients’ decision-making regarding adjuvant treatment. We surveyed patients with breast and colorectal cancer about the importance they assigned to the opinions of their significant others and assessed correlates of these importance scores.

Materials and methods

One hundred and twenty-three patients rated on a five-point scale how much they cared about the opinion of six significant others.

Main results

Most important was the opinion of their treating specialist, followed by that of their partner, children, other family, friends, and colleagues. Women assigned higher scores to the opinion of their children, younger patients to that of their specialist, and patients who were about to undergo chemotherapy to that of their family. Patients with breast cancer and patients without paid employment assigned slightly more importance to the opinion of their partner.

Conclusions

Information on the influence of significant others may help clinicians when involving patients in treatment decision-making and discussing patients’ treatment preferences.

Nur mit Berechtigung zugänglich

Cutoff points for dichotomization were based on statistical efficiency and chosen so that, as much as possible, two equal groups were obtained. For partner and specialist, categories 1 to 4 were grouped (including 58 and 40%, respectively, of the responses); for children and other family, categories 1 to 3 were grouped (including 38 and 63%, respectively); for friends and colleagues, categories 1 to 2 were grouped (including 39 and 53%, respectively).

Ajzen I (1991) The theory of planned behavior. Org Behav Human Decis Process 50:179–211CrossRef

Berry DL, Ellis WJ, Woods NF, Schwien C, Mullen KH, Yang C (2003) Treatment decision-making by men with localized prostate cancer: the influence of personal factors. Urol Oncol 21:93–100PubMed

Bluman LG, Rimer BK, Regan Sterba K, Lancaster J, Clark S, Borstelmann N, Iglehart JD, Winer EP (2003) Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses. Psychooncology 12:410–427PubMedCrossRef

Dodwell DJ (1998) Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions. Lancet 351:1506–1507PubMedCrossRef

Ende J, Kazis L, Ash A, Moskowitz MA (1989) Measuring patients’ desire for autonomy: decision making and information-seeking preferences among medical patients. J Gen Intern Med 4:23–30PubMed

Fishbein M, Ajzen I (1975) Belief, attitude, intention and behavior: an introduction to theory and research. Addison-Wesley, Reading, MA

Harcourt D, Rumsey N (2004) Mastectomy patients’ decision-making for or against immediate breast reconstruction. Psychooncology 13:106–115PubMedCrossRef

Irwin E, Arnold A, Whelan TJ, Reyno LM, Cranton P (1999) Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. Patient Educ Couns 37:283–291PubMedCrossRef

Jansen SJT, Otten W, Baas-Thijssen MCM, Stiggelbout AM (2003) Adjuvant chemotherapy for breast and colorectal cancer: what do patients want, and why? Qual Life Res 12:802

10.

Jansen SJT, Otten W, Stiggelbout AM (2004) A review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol 22:3181–3190PubMedCrossRef

11.

Johnson JD, Roberts CS, Cox CE, Reintgen DS, Levine JS, Parsons M (1996) Breast cancer patients’ personality style, age, and treatment decision making. J Surg Oncol 63:183–186PubMedCrossRef

12.

O’Connor AM, Legare F, Stacey D (2003) Risk communication in practice: the contribution of decision aids. BMJ 327:736–740PubMedCrossRef

13.

Salkeld G, Solomon M, Short L, Butow PN (2004) A matter of trust—patient’s views on decision-making in colorectal cancer. Health Expect 7:104–114PubMedCrossRef

14.

Siminoff LA, Fetting JH (1991) Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med 32:813–818PubMedCrossRef

15.

Stiggelbout AM, Kiebert GM (1997) Patient preferences for information and participation in clinical decision making: a role for the sick role. CMAJ 157:383–389PubMed

16.

Sutherland, HJ, Da Cunha R, Lockwood GA, Till JE (1998) What attitudes and beliefs underlie patients’ decisions about participating in chemotherapy trials? Med Decis Making 18:61–69PubMed

17.

Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I (2003) Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst 95:581–587PubMedCrossRef

Titel: How important is the opinion of significant others to cancer patients’ adjuvant chemotherapy decision-making?
verfasst von: A. M. Stiggelbout
S. J. T. Jansen
W. Otten
M. C. M. Baas-Thijssen
H. van Slooten
C. J. H. van de Velde
Publikationsdatum: 01.03.2007
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 3/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0149-z

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

How important is the opinion of significant others to cancer patients’ adjuvant chemotherapy decision-making?